Development of BAT8001, a HER2 Antibody Drug Conjugate

Time: 9:10 am
day: Day Two

Details:

  • Learn about the ADC, effective against tumors resistant to trastuzumab, that has been developed
  • Assess clinical studies that have determined the effective dose
  • Hear about the GMP compliant production facility that has been constructed to manufacture the commercial product

Speakers: